<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434881</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection.</ArticleTitle><Pagination><StartPage>1477721</StartPage><MedlinePgn>1477721</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1477721</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1477721</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">With the continued prevalence of COVID-19, repeated infection caused by SARS-CoV-2 has become common. However, studies on immune persistence post Omicron XBB reinfection are limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We prospectively studied the durability and cross-reactivity of neutralizing antibodies (NAbs) and T cell responses among 20 subjects who suffered Omicron BA.5 infection with or without Omicron XBB reinfection over 6-month through the pseudovirus neutralization test and the fluorospot assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">NAbs against EG.5.1, BA.2.86, and JN.1 subvariants were decreased and undetectable at 6-month post Omicron BA.5 infection, while those elicited by Omicron XBB reinfection were significant increased and remained detectable against all detected variants within 6-month. Furthermore, in subjects with Omicron XBB reinfection, memory T cell responses could cross-recognized wild-type and Omicron spike peptides and reached peak at 3-month. Interestingly, comparable robust T cell responses were observed among non-seroconverted subjects post Omicron XBB exposure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Though the NAbs against various emerging Omicron subvariants elicited by Omicron XBB reinfection can persist for at least 6-month, the HCWs should strengthen personal protection and timely be immunized with updated vaccines upon current circulating variants or conserved T epitope.</AbstractText><CopyrightInformation>Copyright © 2024 Zhao, Li, Zhang, Chen, Zhao, Wu, Wang, Xu, Lv, Jiang, Wang and Fang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Xin-Jing</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Xin-Lou</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Key Laboratory of Environmental Sense Organ Stress and Health of the Ministry of Environmental Protection, the Ninth Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jin-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei-Chao</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, the Ninth Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Na-Na</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, the Ninth Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rui-Juan</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, the Ninth Medical Center, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Chen-Long</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Bao-Gui</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guo-Lin</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Li-Qun</ForeName><Initials>LQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000084063" MajorTopicYN="Y">Reinfection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091246" MajorTopicYN="Y">Memory T Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron XBB reinfection</Keyword><Keyword MajorTopicYN="N">cross-recognition</Keyword><Keyword MajorTopicYN="N">immune persistence</Keyword><Keyword MajorTopicYN="N">memory T cell responses</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434881</ArticleId><ArticleId IdType="pmc">PMC11491401</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1477721</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fu D, He G, Li H, Tan H, Ji X, Lin Z, et al. . Effectiveness of covid-19 vaccination against sars-cov-2 omicron variant infection and symptoms - China, december 2022-february 2023. China CDC Wkly. (2023) 5:369–73. doi: 10.46234/ccdcw2023.070</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.070</ArticleId><ArticleId IdType="pmc">PMC10184382</ArticleId><ArticleId IdType="pubmed">37197449</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . Statement on the fifteenth meeting of the ihr, in: Emergency committee on the covid-19 pandemic (2005). Available online at: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (Accessed 2024 Feb 18).</Citation></Reference><Reference><Citation>
CDC . Epidemic situation of covid-19 infection in China (2023). Available online at: https://www.Chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/index.html (Accessed 2023 04 December).</Citation></Reference><Reference><Citation>Faraone JN, Qu P, Zheng YM, Carlin C, Jones D, Panchal AR, et al. . Continued evasion of neutralizing antibody response by omicron xbb.1.16. Cell Rep. (2023) 42:113193. doi: 10.1016/j.celrep.2023.113193</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113193</ArticleId><ArticleId IdType="pmc">PMC10872815</ArticleId><ArticleId IdType="pubmed">37777967</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, et al. . Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. (2023) 15:2254. doi: 10.1038/s41467-024-46490-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z, et al. . Transmissibility, infectivity, and immune evasion of the sars-cov-2 ba.2.86 variant. Lancet Infect Dis. (2023) 23:e460–e1. doi: 10.1016/S1473-3099(23)00575-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00575-3</ArticleId><ArticleId IdType="pubmed">37734391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y, Kosugi Y, Uriu K, Ito J, Hinay AA, Jr., Kuramochi J, et al. . Antiviral efficacy of the sars-cov-2 xbb breakthrough infection sera against omicron subvariants including eg.5. Lancet Infect Dis. (2023) 23:e395–e6. doi: 10.1016/S1473-3099(23)00553-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00553-4</ArticleId><ArticleId IdType="pubmed">37708910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zou J, Kurhade C, Deng X, Chang HC, Kim DK, et al. . Less neutralization evasion of sars-cov-2 ba.2.86 than xbb sublineages and ch.1.1. Emerg Microbes Infect. (2023) 12:2271089. doi: 10.1080/22221751.2023.2271089</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2271089</ArticleId><ArticleId IdType="pmc">PMC10606781</ArticleId><ArticleId IdType="pubmed">37824708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ, Li LB, Peng HH, Tian S, Ji B, Shi C, et al. . Neutralization against Xbb.1 and Xbb.1.5 after Omicron Subvariants Breakthrough Infection or Reinfection. Lancet Reg Health West Pac. (2023) 33:100759. doi: 10.1016/j.lanwpc.2023.100759</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100759</ArticleId><ArticleId IdType="pmc">PMC10114502</ArticleId><ArticleId IdType="pubmed">37090240</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankov MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, Morillas Ramos G, Graalmann T, et al. . Humoral and cellular immune responses following bnt162b2 xbb.1.5 vaccination. Lancet Infect Dis. (2024) 24:e1-e3. doi: 10.1016/S1473-3099(23)00690-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00690-4</ArticleId><ArticleId IdType="pubmed">37995739</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N, Trost JF, Guebre-Xabier M, Zhou H, Norton J, Jiang D, et al. . Xbb.1.5 spike protein covid-19 vaccine induces broadly neutralizing and cellular immune responses against eg.5.1 and emerging xbb variants. Sci Rep. (2023) 13:19176. doi: 10.1038/s41598-023-46025-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46025-y</ArticleId><ArticleId IdType="pmc">PMC10628164</ArticleId><ArticleId IdType="pubmed">37932354</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, Bladh O, Aguilera K, Yang Y, Greilert Norin N, Blom K, et al. . Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in Sweden. Lancet Infect Dis. (2024) 24:e80–e1. doi: 10.1016/S1473-3099(23)00779-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00779-X</ArticleId><ArticleId IdType="pubmed">38190833</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, et al. . Neutralization, effector function and immune imprinting of omicron variants. Nature. (2023) 621:592–601. doi: 10.1038/s41586-023-06487-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06487-6</ArticleId><ArticleId IdType="pmc">PMC10511321</ArticleId><ArticleId IdType="pubmed">37648855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. . Imprinted sars-cov-2 humoral immunity induces convergent omicron rbd evolution. Nature. (2023) 614:521–9. doi: 10.1038/s41586-022-05644-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Liu T, Zhao XJ, Liu XL, Li XL, Du KG, et al. . Neutralization against Emerging Omicron Subvariants after Sars-Cov-2 Reinfection. J Infect. (2023) 87:598–601. doi: 10.1016/j.jinf.2023.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.09.013</ArticleId><ArticleId IdType="pubmed">37802470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. . Sars-cov-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. Cell. (2022) 185:847–59 e11. doi: 10.1016/j.cell.2022.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. . Sars-cov-2-reactive T cells in healthy donors and patients with covid-19. Nature. (2020) 587:270–4. doi: 10.1038/s41586-020-2598-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2598-9</ArticleId><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. . Early assessment of the clinical severity of the sars-cov-2 omicron variant in South Africa: A data linkage study. Lancet. (2022) 399:437–46. doi: 10.1016/S0140-6736(22)00017-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00017-4</ArticleId><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A, et al. . Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ. (2020) 371:m3582. doi: 10.1136/bmj.m3582</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3582</ArticleId><ArticleId IdType="pmc">PMC7591828</ArticleId><ArticleId IdType="pubmed">33115726</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernacka P, Piekarska A, Berkan-Kawinska A. Analysis of the prevalence of anti-sars-cov-2 antibodies in groups of medical and non-medical professions. Int J Occup Med Environ Health. (2023) 36:643–55. doi: 10.13075/ijomeh.1896.02162</Citation><ArticleIdList><ArticleId IdType="doi">10.13075/ijomeh.1896.02162</ArticleId><ArticleId IdType="pmc">PMC10702869</ArticleId><ArticleId IdType="pubmed">37768026</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. . Pre-existing polymerase-specific T cells expand in abortive seronegative sars-cov-2. Nature. (2022) 601:110–7. doi: 10.1038/s41586-021-04186-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04186-8</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, et al. . Antibody neutralisation of emerging sars-cov-2 subvariants: eg.5.1 and xbc.1.6. Lancet Infect Dis. (2023) 23:e397–e8. doi: 10.1016/S1473-3099(23)00555-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00555-8</ArticleId><ArticleId IdType="pubmed">37708906</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo N, Wu S, Wang Y, Wang B, Zhang Z, Zhang J, et al. . Monovalent XBB.1.5 booster vaccination induces broad-spectrum of SARS-CoV-2 neutralizing antibodies. Emerg Microbes Infect. (2024) 13:2286260. doi: 10.1080/22221751.2023.2286260</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2286260</ArticleId><ArticleId IdType="pmc">PMC10795553</ArticleId><ArticleId IdType="pubmed">37982743</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, Bladh O, Aguilera K, Yang Y, Greilert-Norin N, Blom K, et al. . Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect Dis. (2024) 24:e80-e81. doi: 10.1016/S1473-3099(23)00779-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00779-X</ArticleId><ArticleId IdType="pubmed">38190833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen CH, Moustsen-Helms IR, Rasmussen M, Soborg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the xbb.1.5 updated covid-19 vaccine against hospitalisation in Denmark: A national cohort study. Lancet Infect Dis. (2024) 24:e73–e4. doi: 10.1016/S1473-3099(23)00746-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00746-6</ArticleId><ArticleId IdType="pubmed">38190834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Bhiman JN, Tempia S, Kleynhans J, Madzorera VS, Mkhize Q, et al. . SARS-CoV-2 correlates of protection from infection against variants of concern. Nat Med. (2024). doi: 10.1038/s41591-024-03131-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03131-2</ArticleId><ArticleId IdType="pubmed">39060660</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Straten K, Guerra D, Kerster G, Claireaux M, Grobben M, Schriek AI, et al. . Primary sars-cov-2 variant of concern infections elicit broad antibody fc-mediated effector functions and memory B cell responses. PloS Pathog. (2024) 20:e1012453. doi: 10.1371/journal.ppat.1012453</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1012453</ArticleId><ArticleId IdType="pmc">PMC11349224</ArticleId><ArticleId IdType="pubmed">39146376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. . Persistence of sars-cov-2-specific B and T cell responses in convalescent covid-19 patients 6-8 months after the infection. Med. (2021) 2:281–95 e4. doi: 10.1016/j.medj.2021.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.02.001</ArticleId><ArticleId IdType="pmc">PMC7874960</ArticleId><ArticleId IdType="pubmed">33589885</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M, Reynaldi A, Lee WS, Nguyen J, Amarasena T, Taiaroa G, et al. . Sars-cov-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity. (2023) 56:879–92 e4. doi: 10.1016/j.immuni.2023.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.02.017</ArticleId><ArticleId IdType="pmc">PMC9970913</ArticleId><ArticleId IdType="pubmed">36958334</ArticleId></ArticleIdList></Reference><Reference><Citation>Atef S, Al Hosani F, AbdelWareth L, Al-Rifai RH, Abuyadek R, Jabari A, et al. . Susceptibility to reinfection with sars-cov-2 virus relative to existing antibody concentrations and T cell response. Int J Infect Dis. (2023) 131:100–10. doi: 10.1016/j.ijid.2023.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9870609</ArticleId><ArticleId IdType="pubmed">36702370</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. . Sars-cov-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. (2020) 11:5064. doi: 10.1038/s41467-020-18848-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18848-0</ArticleId><ArticleId IdType="pmc">PMC7544689</ArticleId><ArticleId IdType="pubmed">33033249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A, Trieu MC, Mohn KGI, Madsen A, Olofsson JS, Sandnes HH, et al. . Risk assessment and antibody responses to sars-cov-2 in healthcare workers. Front Public Health. (2023) 11:1164326. doi: 10.3389/fpubh.2023.1164326</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1164326</ArticleId><ArticleId IdType="pmc">PMC10402899</ArticleId><ArticleId IdType="pubmed">37546332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>